Aktuelles & Neues der YM Biosciences Inc.

Ym Biosciences Reports Daiichi-Sankyo Enrolls First Patients in Phase II, First-Line Lung Cancer Trial With Nimotuzumab

On Tuesday June 23, 2009, 11:48 am EDT

Nimotuzumab Demonstrates Efficacy in Randomized Head & Neck Cancer Study Without the Toxicities Associated With Other Egfr Drugs

On Monday June 1, 2009, 8:09 am EDT

Results from a randomized Phase IIb trial reported at 2009 ASCO Annual Meeting

YM Biosciences Announces Results of Randomized Nimotuzumab Study to be Presented in a Poster at Asco Annual Meeting

On Thursday May 28, 2009, 5:45 pm EDT

YM Biosciences Reports Third Quarter 2009 Operational and Financial Results

On Thursday May 14, 2009, 7:00 am EDT

YM Biosciences Announces First Patient Enrolled in Multi-National, Randomized, Double-Blind Trial of Nimotuzumab in Non-Small-Cell Lung Cancer

MISSISSAUGA, ON, March 16 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide,...